MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. announced positive results from preclinical studies of XmAb®5871, a humanized monoclonal antibody that dually targets CD19 and CD32b (Fc?RIIb) for the treatment of autoimmune diseases, demonstrating that XmAb5871 is a potent suppressor of B cell activation ex vivo and of autoimmune response in humanized mouse models. XmAb5871 consists of an Fc domain engineered by Xencor to produce a 400-fold greater affinity for binding to the CD32b receptor and for co-engaging with the BCR complex. Researchers concluded that XmAb5871 may be an effective immunosuppressant in multiple in vivo settings including systemic lupus erythematosus (SLE), and can globally suppress autoimmune response without B cell depletion. The results are published in the April 1, 2011 issue of The Journal of Immunology.
